Vitamin D3 for Mood & Depression

Table of Contents

1. VDR Expression in Mood-Relevant Brain Regions
2. TPH2 Regulation — The Serotonin-Synthesis Link
3. The Retracted 2016 Trial and the Trial Evidence
4. Observational Data on 25(OH)D and Depression
5. Seasonal Affective Disorder (SAD)
6. Other Proposed Mechanisms — Mostly Animal Studies
7. Anxiety, Premenstrual Symptoms, and Postpartum Depression
8. Cognitive Decline and Alzheimer's
9. Doses Used in Trials and What Guidelines Say
10. Safety Findings
11. Key Research Papers
12. Connections
13. Featured Videos

VDR Expression in Mood-Relevant Brain Regions

The case that vitamin D could matter for the brain starts with where its receptor is found. In 2005, Eyles and colleagues reported the first map of the vitamin D receptor (VDR) and of 1α-hydroxylase (CYP27B1), the enzyme that forms the active vitamin, in the human brain. Both were found in neurons and in glial cells, in a regional and layer-specific pattern that was “strikingly similar” to the one reported in rodents. The strongest staining for both the receptor and the enzyme was in the hypothalamus and in the large, presumably dopaminergic, neurons of the substantia nigra. Some cells, such as the Purkinje cells of the cerebellum, carried the enzyme without the receptor.

Because the enzyme is present, the authors suggested that vitamin D may act in an autocrine/paracrine way in the human brain — that brain cells may make active vitamin D locally — and that it operates in a similar fashion to the known neurosteroids.

A 2014 study by the same group confirmed the receptor in adult rodent brain with proteomic methods, noting that earlier antibody-based studies had been disputed. It also found that VDR expression is quantitatively lower in the brain than in classic target organs such as the gut and kidney.

Back to Table of Contents

TPH2 Regulation — The Serotonin-Synthesis Link

The most direct molecular link proposed between vitamin D and mood involves tryptophan hydroxylase (TPH), the enzyme that makes serotonin. There are two forms: TPH2 in the brain and TPH1 in tissues outside the blood-brain barrier.

Patrick and Ames (2014, FASEB Journal) presented evidence that the vitamin D hormone (calcitriol) activates transcription of the TPH2 gene in the brain at a vitamin D response element (VDRE), and represses transcription of TPH1 outside the blood-brain barrier at a distinct VDRE. Their paper proposed this mechanism as an explanation for features of autism, including low serotonin in the brain alongside raised serotonin outside it; it was not a depression study.

The implication drawn for mood — that low vitamin D could reduce brain serotonin synthesis — is a hypothesis. Berridge (2017), reviewing the cellular mechanisms, wrote that “just how vitamin D acts to reduce depression is unclear,” and proposed a different route: that vitamin D maintains the calcium pumps and buffers that keep neuronal calcium levels in check.

Back to Table of Contents

The Retracted 2016 Trial and the Trial Evidence

Sepehrmanesh et al. (2016, Journal of Nutrition) reported an 8-week trial of vitamin D 50,000 IU/week versus placebo in 40 patients with major depressive disorder. Its abstract reported a trend toward a greater fall in Beck Depression Inventory scores with vitamin D that did not reach statistical significance (−8.0 versus −3.3, P = 0.06), along with changes in insulin resistance and oxidative-stress markers. The journal placed an expression of concern on the paper in 2020 (notice PubMed PMID: 33097954) and retracted it in 2021 (notice PubMed PMID: 33974698). Its reported figures can no longer be relied on.

Meta-analyses of supplementation trials

• Spedding 2014 (Nutrients) — 15 RCTs. Studies without “biological flaws” (for example, those in which vitamin D levels actually changed) showed a statistically significant improvement in depression; studies with such flaws were mainly inconclusive. This analysis predates, and so does not include, the retracted 2016 trial.
• Gowda 2015 (Nutrition) — nine trials, 4,923 participants. No significant reduction in depression was seen overall (standardized mean difference 0.28, 95% CI −0.14 to 0.69); most studies enrolled people with low levels of depression and sufficient baseline vitamin D. It also predates the retracted trial.
• Vellekkatt 2019 (Journal of Postgraduate Medicine) — four trials in clinically diagnosed major depression, 948 participants. Pooled effect size 0.58 (95% CI 0.45-0.72), which the authors called moderate and “tentative owing to the limited number of trials available and inherent methodological bias.” The Sepehrmanesh 2016 trial is one of the four trials it pooled (its Table 1), so this pooled estimate includes a since-retracted trial.
• Cheng 2020 (Depression and Anxiety) — 25 trials, 7,534 participants, measuring “negative emotions.” It found an overall effect of vitamin D (Hedges' g −0.50) but with very high heterogeneity (I² 97.7%), which the authors said calls for caution. In subgroups, the effect was seen in patients with major depressive disorder and in people with 25(OH)D at or below 50 nmol/L; the authors concluded that these two groups are “most likely to benefit.”
• Ghaemi 2024 (Psychological Medicine) — a dose-response meta-analysis of 31 trials, 24,189 participants. Each 1,000 IU/day of vitamin D3 was associated with a slight reduction in depressive symptoms (SMD −0.32), larger in people with depressive symptoms (SMD −0.57). Trials of up to 24 weeks showed stronger effects; trials lasting 24 to 52 weeks (SMD −0.13, 95% CI −0.28 to 0.02) or longer than 52 weeks (SMD 0.14, 95% CI −0.16 to 0.44) did not show a significant effect. The authors summarized that vitamin D3 “may effectively reduce depressive symptoms in short term.”

The VITAL-DEP prevention trial

Okereke et al. (2020, JAMA) randomized 18,353 adults aged 50 or older, without clinically relevant depressive symptoms at baseline, to vitamin D3 2,000 IU/day or placebo for a median of 5.3 years. The risk of depression or clinically relevant depressive symptoms did not differ significantly between groups (hazard ratio 0.97, 95% CI 0.87-1.09), and mood scores did not change differently. The authors concluded that the findings “do not support the use of vitamin D3 in adults to prevent depression.” The trial tested prevention in people without depressive symptoms at the start, not treatment of diagnosed depression.

Back to Table of Contents

Observational Data on 25(OH)D and Depression

Observational studies link lower 25(OH)D with depression:

• Anglin 2013 (British Journal of Psychiatry) — systematic review and meta-analysis of one case-control, ten cross-sectional and three cohort studies (31,424 participants). Vitamin D levels were lower in people with depression than in controls. In the cross-sectional studies, the odds ratio of depression for the lowest versus highest vitamin D category was 1.31 (95% CI 1.0-1.71); in the cohort studies the hazard ratio was 2.21 (95% CI 1.40-3.49). The authors called for randomized trials to find out whether the association is causal.
• Young women — in 185 female undergraduates in the US Pacific Northwest (Kerr 2015), lower vitamin D3 at the start predicted clinically significant depressive symptoms over the following four weeks, after adjusting for season, BMI, diet, exercise and time outside; depressive symptoms did not predict later change in vitamin D.
• Pregnancy and after birth — a 2018 meta-analysis of nine longitudinal studies linked 25(OH)D below 50 nmol/L with a higher risk of postpartum depression (see below).

Observational data cannot establish causality — the correlation could reflect reverse causation or unmeasured confounders. The trial evidence on whether supplementation changes depression outcomes is mixed (see above), so the proposed mechanisms are not yet matched by consistent trial results.

Back to Table of Contents

Seasonal Affective Disorder (SAD)

Seasonal Affective Disorder (SAD) is a mood disorder with a seasonal pattern. The condition itself — symptoms, diagnosis, and the trial evidence for light therapy, medicines and talking therapy — is covered on the Seasonal Affective Disorder page.

The vitamin D hypothesis for SAD rests on seasonal timing. A 2014 hypothesis paper (Stewart et al., Medical Hypotheses) argued that vitamin D plays a “foundational and regulative” rather than direct role in SAD, giving as reasons that vitamin D levels fluctuate seasonally, with a lag, with available sunlight; that lower levels have been observed in depressed patients; that vitamin D in the central nervous system affects serotonin and dopamine production; and that vitamin D response elements are concentrated in the hypothalamus, which holds much of the circadian timing system. It also proposed that people with darker skin who move to higher latitudes may face a greater risk of low vitamin D.

The trials have not borne out a clear benefit:

• A 1999 trial in 15 people with SAD (Gloth et al.) compared a single 100,000 IU dose of vitamin D with broad-spectrum phototherapy; the vitamin D group improved on all depression scales after one month, while the phototherapy group showed no significant change. The authors said further studies were needed to confirm this.
• In a randomized, double-blind trial in 34 healthcare workers with seasonal symptoms (Frandsen et al. 2014), 70 µg of vitamin D daily for 3 months did not differ from placebo on SAD symptoms; both groups improved over the winter-to-spring period. The authors noted the trial was underpowered and could not assess people with low 25(OH)D.
• A 2020 systematic review of eleven studies found that neither vitamin D nor vitamin B12 supplementation showed benefit for SAD, and that no nutrition intervention had demonstrated efficacy for SAD symptoms (Yang et al. 2020).

Back to Table of Contents

Other Proposed Mechanisms — Mostly Animal Studies

Beyond serotonin synthesis, several other routes have been proposed. Most of the evidence for them comes from laboratory and rodent studies, not from people.

• Inflammation, oxidative stress and neurotrophic effects — a 2026 review of preclinical studies in rodent models (Camargo and Rodrigues) describes accumulating evidence for antioxidant, neurotrophic and anti-inflammatory effects of vitamin D-dependent pathways in the central nervous system, and proposes that, by influencing neurotransmitter synthesis, neuroinflammatory and redox pathways and neuroplasticity, vitamin D signaling may contribute to mechanisms underlying depressive symptoms. The review's stated aim is to identify targets for future translational studies.
• Neuronal calcium — Berridge (2017) proposed the “phenotypic stability hypothesis”: that vitamin D lowers raised calcium levels in neurons by maintaining the expression of calcium pumps and buffers.
• Neurosteroid-like action — a 2010 review of 127 articles (Annweiler et al.) concluded that vitamin D may act like a neurosteroid hormone in neurotransmission, neuroprotection and neuroimmunomodulation during brain development.

These are hypotheses about how vitamin D could affect mood; they do not show that supplements do, which is the question the trials above address.

Back to Table of Contents

Anxiety, Premenstrual Symptoms, and Postpartum Depression

Anxiety

The 2024 dose-response meta-analysis (Ghaemi et al.) that found a short-term effect on depressive symptoms found that vitamin D3 supplementation had no significant effect on anxiety symptoms, and called for further high-quality trials. The 2020 meta-analysis by Cheng and colleagues pooled depression and anxiety outcomes together as “negative emotions” (see above), so it does not give a separate answer for anxiety.

Premenstrual Syndrome (PMS)

In a case-control study nested within the Nurses' Health Study II (Bertone-Johnson 2005; 1,057 women who developed PMS over 10 years and 1,968 comparison women), women in the highest fifth of total vitamin D intake (median 706 IU/day) had a relative risk of PMS of 0.59 (95% CI 0.40-0.86) compared with the lowest fifth (median 112 IU/day); calcium from food sources was also inversely related to PMS (relative risk 0.70). The authors called for large clinical trials. A 2019 systematic review and meta-analysis of 16 studies (Arab et al.) found no significant association between blood 25(OH)D and PMS in observational studies, but reported that vitamin D supplementation improved PMS symptoms in the interventional studies, and called for further well-designed trials. Neither paper studied premenstrual dysphoric disorder (PMDD) specifically.

Postpartum Depression

A 2018 meta-analysis of nine longitudinal studies with 8,470 participants (Wang et al.) found that 25(OH)D below 50 nmol/L was associated with a higher risk of postpartum depression (odds ratio 3.67, 95% CI 1.72-7.85) compared with levels of 50 nmol/L or above, but found no significant link between low vitamin D and depressive symptoms during pregnancy (odds ratio 1.47, 95% CI 0.92-2.36, at a 30 nmol/L cut-off). The authors said the result should be interpreted with caution because of the small number of studies, and that intervention studies are needed. Separately, the 2024 Endocrine Society guideline suggests empiric vitamin D in pregnancy because of its potential to lower the risk of preeclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth and neonatal mortality; depression is not among the outcomes its abstract lists.

Back to Table of Contents

Cognitive Decline and Alzheimer's

In the US Cardiovascular Health Study (Littlejohns 2014, Neurology), 1,658 older adults free of dementia were followed for a mean of 5.6 years. Compared with people with sufficient 25(OH)D (50 nmol/L or more), those who were severely deficient (below 25 nmol/L) had an adjusted hazard ratio of 2.25 (95% CI 1.23-4.13) for all-cause dementia and 2.22 (95% CI 1.02-4.83) for Alzheimer disease; for those who were deficient (25 to below 50 nmol/L) the figures were 1.53 and 1.69. Risk rose markedly below a threshold of 50 nmol/L. This is an observational association; the authors described it as adding to the debate about vitamin D's role outside bone.

The 2010 review by Annweiler and colleagues reported that in older adults, low vitamin D has been associated with neuromuscular disorders, dementia and Parkinson's disease, and the authors proposed that supplementation might have a protective effect — a proposal, not a trial result.

Back to Table of Contents

Doses Used in Trials and What Guidelines Say

The doses below are those the studies on this page used, as they report them; they are not a regimen.

• VITAL-DEP — 2,000 IU/day of vitamin D3 for a median of 5.3 years in adults aged 50 and over; no effect on depression risk or mood scores.
• Frandsen 2014 — 70 µg/day for 3 months in people with seasonal symptoms; no difference from placebo.
• Gloth 1999 — a single 100,000 IU dose in 15 people with SAD; improvement reported in a very small trial.
• Sepehrmanesh 2016 — 50,000 IU/week for 8 weeks; retracted.
• Cheng 2020 — in pooled data, trials lasting 8 weeks or more and using 4,000 IU/day or less showed an effect on negative emotions.
• Ghaemi 2024 — the effect per 1,000 IU/day was significant in pooled trials of up to 24 weeks but not in trials lasting longer than 24 weeks.

Some practitioners describe mood-support protocols that combine vitamin D with omega-3 fatty acids, B vitamins and magnesium (see the Vitamin D3 overview). The individual trials described on this page tested vitamin D against placebo or, in one small trial, against phototherapy.

Blood levels and testing

The 2024 Endocrine Society guideline (Demay et al.), written for people without an established reason for vitamin D treatment or testing, found “no clear evidence defining the optimal target level of 25(OH)D required for disease prevention,” and suggests against routine 25(OH)D testing in the populations it considered. It suggests against empiric vitamin D above the Dietary Reference Intakes to lower disease risk in healthy adults younger than 75, and states that optimal doses for empiric supplementation remain unclear. Its recommendations do not apply to people with established indications for vitamin D treatment or testing. Guideline cut-points for deficiency and sufficiency are set out on the Vitamin D3 overview.

Depression has many causes and treatments; decisions about testing, supplements and depression treatment belong with a clinician.

Back to Table of Contents

Safety Findings

• Vitamin D toxicity — a 2018 clinical review (Marcinowska-Suchowierska et al.) lists confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia and dehydration as the most often noted symptoms of vitamin D toxicity, whose clinical manifestation is severe hypercalcemia. Some of these, such as confusion and apathy, overlap with symptoms of a mood disorder. The review describes serum 25(OH)D above 150 ng/mL (375 nmol/L) as the hallmark of toxicity from overdosing, usually from inadvertent or improper intake of extremely high doses.
• Granulomatous disorders and some lymphomas — the same review describes toxicity arising from excess production of active vitamin D (1,25(OH)₂D) in granulomatous disorders and in some lymphomas, and describes “hypersensitivity to vitamin D,” in which asymptomatic hypercalcemia appears even at doses considered safe for the general population.

Back to Table of Contents

Key Research Papers

1. Sepehrmanesh Z, Kolahdooz F, Abedi F, et al. (2016). Vitamin D supplementation affects the Beck Depression Inventory, insulin resistance, and biomarkers of oxidative stress in patients with major depressive disorder: a randomized, controlled clinical trial. Journal of Nutrition 146:243-248. — PubMed PMID: 26609167 — Retracted (retraction notice: PubMed PMID: 33974698)
2. Anglin RES, Samaan Z, Walter SD, McDonald SD (2013). Vitamin D deficiency and depression in adults: systematic review and meta-analysis. British Journal of Psychiatry 202:100-107. — PubMed PMID: 23377209
3. Patrick RP, Ames BN (2014). Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism. FASEB Journal 28:2398-2413. (The TPH2 mechanism paper.) — PubMed PMID: 24558199
4. Spedding S (2014). Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients 6:1501-1518. — PubMed PMID: 24732019
5. Cuomo A, Giordano N, Goracci A, Fagiolini A (2017). Depression and vitamin D deficiency: causality, assessment, and clinical practice implications. Neuropsychiatry 7(5). — doi:10.4172/neuropsychiatry.1000255
6. Littlejohns TJ, Henley WE, Lang IA, et al. (2014). Vitamin D and the risk of dementia and Alzheimer disease. Neurology 83:920-928. — PubMed PMID: 25098535
7. Annweiler C, Schott AM, Berrut G, et al. (2010). Vitamin D and ageing: neurological issues. Neuropsychobiology. — PubMed PMID: 20628264
8. Bertone-Johnson ER, Hankinson SE, Bendich A, et al. (2005). Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. — PubMed PMID: 15956003
9. Kerr DCR, Zava DT, Piper WT, et al. (2015). Associations between vitamin D levels and depressive symptoms in healthy young adult women. Psychiatry Research. — PubMed PMID: 25791903
10. Stewart AE, Roecklein KA, Tanner S, Kimlin MG (2014). Possible contributions of skin pigmentation and vitamin D in a polyfactorial model of seasonal affective disorder. Medical Hypotheses. — PubMed PMID: 25270233
11. Eyles DW, Liu PY, Josh P, Cui X (2014). Intracellular distribution of the vitamin D receptor in the brain: comparison with classic target tissues and redistribution with development. Neuroscience. — PubMed PMID: 24607320
12. Vellekkatt F, Menon V (2019). Efficacy of vitamin D supplementation in major depression: a meta-analysis of randomized controlled trials. J Postgrad Med 65:74-80. — PubMed PMID: 29943744 (Note: its four pooled trials include the since-retracted Sepehrmanesh 2016 trial.)
13. Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AM (2015). Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. Nutrition 31:421-429. — PubMed PMID: 25701329
14. Okereke OI, Reynolds CF 3rd, Mischoulon D, et al. (2020). Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA 324:471-480. — PubMed PMID: 32749491
15. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005). Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29:21-30. — PubMed PMID: 15589699
16. Cheng YC, Huang YC, Huang WL (2020). The effect of vitamin D supplement on negative emotions: a systematic review and meta-analysis. Depress Anxiety 37:549-564. — PubMed PMID: 32365423
17. Ghaemi S, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S (2024). The effect of vitamin D supplementation on depression: a systematic review and dose-response meta-analysis of randomized controlled trials. Psychol Med 54:3999-4008. — PubMed PMID: 39552387
18. Frandsen TB, Pareek M, Hansen JP, Nielsen CT (2014). Vitamin D supplementation for treatment of seasonal affective symptoms in healthcare professionals: a double-blind randomised placebo-controlled trial. BMC Res Notes 7:528. — PubMed PMID: 25125215
19. Gloth FM 3rd, Alam W, Hollis B (1999). Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging 3:5-7. — PubMed PMID: 10888476
20. Yang Y, Zhang S, Zhang X, Xu Y, Cheng J, Yang X (2020). The role of diet, eating behavior, and nutrition intervention in seasonal affective disorder: a systematic review. Front Psychol 11:1451. — PubMed PMID: 32903693
21. Wang J, Liu N, Sun W, Chen D, Zhao J, Zhang W (2018). Association between vitamin D deficiency and antepartum and postpartum depression: a systematic review and meta-analysis of longitudinal studies. Arch Gynecol Obstet 298:1045-1059. — PubMed PMID: 30264203
22. Arab A, Golpour-Hamedani S, Rafie N (2019). The association between vitamin D and premenstrual syndrome: a systematic review and meta-analysis of current literature. J Am Coll Nutr 38:648-656. — PubMed PMID: 31074708
23. Berridge MJ (2017). Vitamin D and depression: cellular and regulatory mechanisms. Pharmacol Rev 69:80-92. — PubMed PMID: 28202503
24. Camargo A, Rodrigues ALS (2026). Vitamin D in major depressive disorder: current evidence, possible molecular mechanisms, and future prospects. J Steroid Biochem Mol Biol 260:107003. — PubMed PMID: 41895384
25. Demay MB, Pittas AG, Bikle DD, et al. (2024). Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 109:1907-1947. — PubMed PMID: 38828931
26. Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G (2018). Vitamin D toxicity — a clinical perspective. Front Endocrinol (Lausanne) 9:550. — PubMed PMID: 30294301

PubMed Topic Searches

1. PubMed: vitamin D depression supplementation RCT
2. PubMed: vitamin D TPH2 serotonin synthesis
3. PubMed: vitamin D seasonal affective disorder
4. PubMed: vitamin D BDNF hippocampus neurogenesis
5. PubMed: VDR brain expression hippocampus
6. PubMed: vitamin D anxiety postpartum depression

Back to Table of Contents

Connections

• All Vitamins
• Vitamin D3 Overview
• D3 Benefits Hub
• D3 for Bone Health
• D3 for Immune Function
• D3 for Autoimmune Disease
• Depression
• Anxiety
• Bipolar Disorder
• Alzheimer's Disease
• Tryptophan
• Tyrosine
• Folate / Methylfolate
• Vitamin B12
• Magnesium
• Omega-3 Fatty Acids
• Vitamin D Test
• Deficiency
• Toxicity
• History
• Sources

Back to Table of Contents

Featured Videos